All News
Filter News
Found 22,148 articles
-
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
4/11/2024
FibroBiologics, Inc. announced the issuance of a patent from the Australian Patent Office covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells.
-
7 Billion-Dollar Oncology M&As from Q1
4/10/2024
AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot. -
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
4/10/2024
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with Johnson & Johnson1 to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
-
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
4/9/2024
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test.
-
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
4/9/2024
enGene Holdings Inc. today announced that Raj Pruthi MD MHA FACS has joined the Company as SVP, Urologic Oncology and Clinical Development, reporting to enGene's Chief Medical Officer, Dr. Richard Bryce.
-
Biomarkers Market Size To Hit USD 284.76 Billion By 2033
4/9/2024
According to Nova One Advisor, the global biomarkers market size was exhibited at USD 81.19 billion in 2023 and is projected to hit around USD 284.76 billion by 2033, growing at a CAGR of 13.37% during the forecast period 2024 to 2033.
-
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
4/9/2024
Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.
-
American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer
4/9/2024
Lung cancer remains the leading cause of cancer deaths in the United States, with someone diagnosed approximately every two minutes.
-
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
4/9/2024
CareDx, Inc. today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions, taking place from April 10-13 in Prague, Czech Republic.
-
Cancer Immunotherapy Market Size to Increase USD 280.11 BN by 2033
4/8/2024
According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.
-
The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation
4/8/2024
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib).
-
U.S. Cell Therapy Market Size to Hit USD 19.67 Billion By 2033
4/8/2024
The global U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is poised to grow from USD 3.49 billion in 2024 to USD 19.67 billion by 2033, growing at a CAGR of 21.18% in the forecast period (2024-2033).
-
Aster Insights Announces Research Partnership with FDA to Study the Effects of Patient Demographics on Diagnostic Indicators Used for Checkpoint Inhibitor Therapy
4/8/2024
Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a research collaboration with the Food and Drug Administration (FDA).
-
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
4/8/2024
Johnson & Johnson announced a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® was associated with a reduced risk of clinically significant bleeding, and net adverse clinical events or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention, a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.
-
Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences
4/8/2024
Domain Therapeutics announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024: This press release features multimedia.
-
Zura Bio Announces Robert Lisicki as CEO and Director
4/8/2024
Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.
-
Model N to be Acquired by Vista Equity Partners For $1.25 Billion
4/8/2024
Model N announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners, a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.
-
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
4/8/2024
Gain Therapeutics, Inc. announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
-
Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
4/8/2024
ANGLE plc is pleased to announce its participation at the American Association for Cancer Research Annual Meeting, San Diego, US between 5 to 10 April 2024.
-
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
4/8/2024
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium.